Landmark Wealth Management (New York)’s GSK GSK Stock Holding History

Landmark Wealth Management (New York)’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$593K	Buy	+10,737	New	+$582K	0.16%	100

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Landmark Wealth Management (New York)'s GSK Position: Q1 2026 in Review

Landmark Wealth Management (New York) opened a new position in GSK (GSK) in Q1 2026: 10,737 shares worth $593K. The stake represents 0.16% of the portfolio and ranks #100 among its holdings.

1,033 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Landmark Wealth Management (New York) held 10,737 shares of GSK worth $593K as of Q1 2026.
GSK was a new Landmark Wealth Management (New York) position in Q1 2026.
GSK made up 0.16% of Landmark Wealth Management (New York)'s portfolio in Q1 2026, its #100 holding.
1,033 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Landmark Wealth Management (New York)'s 13F filing for Q1 2026, filed 29 Apr 2026.